Status:
RECRUITING
Understanding the Health Effect of a Bioactive Peptide From Egg: A Pilot Study
Lead Sponsor:
University of Alberta
Conditions:
High Blood Sugar
High Blood Pressure
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
Brief Summary
Bioactive peptides derived from food proteins show potential for improving human health. One of such promising peptides is namely IRW made from egg white hydrolysate and composed of three peptides. Th...
Detailed Description
Bioactive peptides derived from food proteins show vast potential for improving human health, in addition to providing nutritional value. One of such promising peptides is a short tripeptide IRW (made...
Eligibility Criteria
Inclusion
- Healthy control group:
- Men and women aged between 18 and 70 years living in Edmonton (or Edmonton area/driving distance).
- Normal weight (BMI below 25 kg/m2 or Asian population below 23 kg/m2 )
- Waist circumference below the following ethnic specific cut offs: Canada / USA: \<102 cm men and \<88 cm women; Europids, Middle-Eastern, Sub-Saharan African, and Mediterranean: \<94 cm men and \<80 cm women; Asians, Japanese, South and Central Americans: \<90 cm men and \<80 cm women
- Fasting glucose \<5.6 mmol/L
- HbA1c \<5.6 %
- Blood pressure \<130/85 mmHg
- Triglycerides \<1.7 mmol/L
- HDL-Cholesterol \>1.03 mmol/L men and \>1.29 mmol/L women
- Body weight stable (within 3% fluctuation) for at least 6 months prior to the study
- Individuals who have never smoke, have smoke less than 100 cigarettes in their life or who are long term quitter (quit smoking a year or more ago)
- Individuals at risk of diabetes/having type 2 diabetes:
- Men and women aged between 18 and 70 years living in Edmonton (or Edmonton area/driving distance).
- Overweight or obesity (BMI above 25 kg/m2 or Asian population above 23 kg/m2)
- Waist circumference at or above the following ethnic specific cut offs: Canada / USA: ≥ 102 cm men and ≥ 88 cm women; Europids, Middle-Eastern, Sub-Saharan African, and Mediterranean: ≥ 94 cm men and ≥ 80 cm women; Asians, Japanese, South and Central Americans: ≥ 90 cm men and ≥ 80 cm women
- Fasting glucose ≥ 6.0 mmol/L
- HbA1c ≥ 6.0 %
- Body weight stable (within 3% fluctuation) for at least 6 months prior to the study
- Individuals who have never smoke, have smoke less than 100 cigarettes in their life or who are long term quitter (quit smoking a year or more ago)
Exclusion
- Individuals with a previous history of CVD, renal disorder, monogenic dyslipidemia, with endocrine disorders other than T2D
- Individuals taking chronic anti-inflammatory drugs (including aspirin, antihistamines, and omega-3 supplements)
- Pregnant/lactating women
- Individuals aged above 70 years
- Smokers (current smokers: daily/occasional and those who have smoked more than 100 cigarettes in their life)
- Individuals with specific nutritional restrictions (e.g. vegetarianism excluding eggs from their diet, vegan or with egg allergy) will be excluded
- Individuals with poorly controlled (HbA1c \>12.0%) diabetes or taking exogenous insulin will be excluded. Other anti-diabetic and lipid-lowering medications will be documented.
Key Trial Info
Start Date :
January 7 2026
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2026
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT06555393
Start Date
January 7 2026
End Date
October 1 2026
Last Update
January 9 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alberta
Edmonton, Alberta, Canada, T6G 2P5